Vesalius Longevity Labs Inc. filed a Form D with the SEC, reporting $30.1M sold, of a $30.1M offering.

{
  "signal_id": "fd-0002060755-26-000064",
  "signal_type": "sec-form-d-funding",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-11-03T00:00:00+00:00",
  "company": {
    "name": "Vesalius Longevity Labs Inc.",
    "domain": "vesaliuslabs.com"
  },
  "data": {
    "cik": "0002131865",
    "phone": "604-307-8290",
    "detail": "The stock consideration suggests Vesalius is consolidating capabilities or assets rather than simply adding operating capital, which often comes with integration work, process standardization, and expanded commercial coordination. Vendors should pay attention to needs around pharmacy connectivity, prescription workflow software, QA/COA documentation, regulatory support, manufacturing/supply chain tooling, and customer operations as the combined platform settles in.",
    "topics": [
      "Pharmaceuticals",
      "M&A",
      "Longevity",
      "Peptides",
      "Healthcare Services"
    ],
    "summary": "Vesalius Longevity Labs Inc. provides patient-specific peptide prescriptions by connecting licensed prescribers with participating pharmacies and supplying quality documentation for the products it offers. This Form D reflects an acquisition paid in stock of $30,112,500, which signals a meaningful business combination and is relevant to vendors serving pharma operations, pharmacy networks, and compliance-heavy healthcare workflows.",
    "website": "https://vesaliuslabs.com",
    "location": "VANCOUVER, BRITISH COLUMBIA, CANADA",
    "file_date": "2026-11-03",
    "form_type": "D",
    "relevance": 0.62,
    "confidence": "high",
    "exemptions": [
      "06b"
    ],
    "filing_url": "https://www.sec.gov/Archives/edgar/data/2131865/000206075526000064/",
    "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002131865&type=D&dateb=&owner=include&count=40",
    "entity_name": "Vesalius Longevity Labs Inc.",
    "entity_type": "Corporation",
    "jurisdiction": "BRITISH COLUMBIA, CANADA",
    "primary_topic": "Pharma M&A",
    "revenue_range": "Decline to Disclose",
    "industry_group": "Pharmaceuticals",
    "related_persons": [
      {
        "name": "PRADEEP ALBERT",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "CHRISTOPHER COOPER",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "TIMMI STUMP",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "JAMES MCROBERTS",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "KEVIN SERRE",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "ROBERT MCCUE",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "JOEL LEONOFF",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "KEVIN MAYER",
        "roles": [
          "Director"
        ]
      }
    ],
    "total_investors": 62,
    "accession_number": "0002060755-26-000064",
    "securities_types": [
      "Equity"
    ],
    "business_location": "Vancouver",
    "total_amount_sold": 30112500,
    "resolved_entity_name": "Vesalius Longevity Labs",
    "resolved_entity_type": "operating_company",
    "total_offering_amount": 30112500,
    "company_domain_confidence": 10,
    "has_non_accredited_investors": false
  }
}

curl https://signals.autobound.ai/v1/signals/fd-0002060755-26-000064 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"vesaliuslabs.com","limit":20}'